Publications by authors named "Quentin Jarrion"
Article Synopsis
- The study investigates the market share and cost savings from the use of biosimilars to anti-TNF agents in French hospitals, five years after their introduction.
- Results show that the penetration rates for biosimilars are around 74% to 77% for major anti-TNF drugs like infliximab, etanercept, and adalimumab.
- Over this period, the use of biosimilars has led to an estimated total cost saving of 824 million Euros compared to the original drug prices.
Competition From Biosimilars Drives Price Reductions For Biologics In The French Single-Payer Health System.
Health Aff (Millwood)
August 2021
Article Synopsis
- France has a single-payer health system that can lower drug prices but often depends on hospital-manufacturer negotiations for pricing of injected biologics.
- Hospitals use biosimilars, which are cheaper alternatives to costly biologics, to encourage price competition in the market.
- An analysis of biologics from 2004-2020 shows that the introduction of biosimilars leads to price drops for both the original medications and other similar treatments, offering insights for the U.S. on how to utilize biosimilars for cost savings.
Introduction: Signal detection from healthcare databases is possible, but is not yet used for routine surveillance of drug safety. One challenge is to develop methods for selecting signals that should be assessed with priority.
Aim: The aim of this study was to develop an automated system combining safety signal detection and prioritization from healthcare databases and applicable to drugs used in chronic diseases.